Rxi Pharmaceuticals (RXII) Fundamental Analysis & Valuation
NASDAQ:RXII
Current stock price
0.33
0 (0%)
At close:
0.33
0 (0%)
After Hours:
This RXII fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
No Fundamental Analysis report for RXII not available.
RXII Fundamentals: All Metrics, Ratios and Statistics
0.33
0 (0%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners9.91%
Inst Owner ChangeN/A
Ins Owners789.55%
Ins Owner Change0%
Market Cap1.45M
Revenue(TTM)138.00K
Net Income(TTM)-7.63M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)0%
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.47 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.83 | ||
| P/tB | N/A | ||
| EV/EBITDA | 0.24 |
EPS(TTM)-3.3
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.03
BVpS0.4
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -200.45% | ||
| ROE | -436.29% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -5522.46% | ||
| PM (TTM) | -5532.61% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.76 | ||
| Altman-Z | -36.61 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.18%
EPS Next Y63.1%
EPS Next 2Y68.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.05%
Revenue growth 3YN/A
Revenue growth 5Y-19.13%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
Rxi Pharmaceuticals / RXII Fundamental Analysis FAQ
What is the ChartMill fundamental rating of Rxi Pharmaceuticals (RXII) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RXII.
What is the valuation status of Rxi Pharmaceuticals (RXII) stock?
ChartMill assigns a valuation rating of 3 / 10 to Rxi Pharmaceuticals (RXII). This can be considered as Overvalued.
What is the profitability of RXII stock?
Rxi Pharmaceuticals (RXII) has a profitability rating of 1 / 10.
Can you provide the financial health for RXII stock?
The financial health rating of Rxi Pharmaceuticals (RXII) is 1 / 10.
What is the earnings growth outlook for Rxi Pharmaceuticals?
The Earnings per Share (EPS) of Rxi Pharmaceuticals (RXII) is expected to grow by 63.1% in the next year.